Incidentaloma laboratory findings

Jump to navigation Jump to search

Incidentaloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Incidentaloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Incidentaloma laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Incidentaloma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Incidentaloma laboratory findings

CDC on Incidentaloma laboratory findings

Incidentaloma laboratory findings in the news

Blogs on Incidentaloma laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Incidentaloma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Laboratory findings consistent with the diagnosis of incidentaloma include an abnormal 1 mg overnight dexamethasone for subclinical Cushing's syndrome that should be confirmed with 24-hour urinary free cortisol, serum ACTH concentration, and dehydroepiandrosterone sulfate (DHEAS). In patients with adrenal masses that have a probability for pheochromocytoma, routine measurement of 24-hour urinary fractionated metanephrines and catecholamines should be done. All patients with hypertension and an adrenal incidentaloma should be evaluated by measurements of plasma aldosterone concentration and plasma renin activity.

Laboratory Findings

Subclinical Cushing's syndrome

Pheochromocytoma

Hyperaldosteronism|Aldosteronomas

  • All patients with hypertension and an adrenal incidentaloma should be evaluated by measurements of plasma aldosterone concentration and plasma renin activity.
  • Measurement of plasma aldosterone to renin ratio (ARR) is the best initial test for the evaluation of primary aldosteronism (44, 106, 111). A range of ARR cutoff values from 20 to 100
  • A serum aldosterone level below 0.25 nmol/liter (9 ng/dl) makes a diagnosis of primary aldosteronism highly unlikely.[5]
  • Borderline values should be repeated:[6]
  1. After correcting hypokalemia
  2. While the patient is on salt restriction
  3. In the morning in a sitting position
  4. After resting for at least 15 min before proceeding with confirmatory tests
  • Patients with an elevated ARR should proceed with a confirmatory test such as the salt loading test or saline suppression test.[6][7]

References

  1. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM; et al. (2008). "The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab. 93 (5): 1526–40. doi:10.1210/jc.2008-0125. PMC 2386281. PMID 18334580.
  2. Eller-Vainicher C, Morelli V, Salcuni AS, Torlontano M, Coletti F, Iorio L; et al. (2010). "Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery?". Eur J Endocrinol. 162 (1): 91–9. doi:10.1530/EJE-09-0775. PMID 19797503.
  3. Katabami T, Obi R, Shirai N, Naito S, Saito N (2005). "Discrepancies in results of low-and high-dose dexamethasone suppression tests for diagnosing preclinical Cushing's syndrome". Endocr J. 52 (4): 463–9. PMID 16127216.
  4. Young WF (2007). "Clinical practice. The incidentally discovered adrenal mass". N Engl J Med. 356 (6): 601–10. doi:10.1056/NEJMcp065470. PMID 17287480.
  5. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J; et al. (2003). "Primary aldosteronism and hypertensive disease". Hypertension. 42 (2): 161–5. doi:10.1161/01.HYP.0000079505.25750.11. PMID 12796282.
  6. 6.0 6.1 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M; et al. (2008). "Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline". J Clin Endocrinol Metab. 93 (9): 3266–81. doi:10.1210/jc.2008-0104. PMID 18552288.
  7. Mitchell IC, Auchus RJ, Juneja K, Chang AY, Holt SA, Snyder WH; et al. (2007). ""Subclinical Cushing's syndrome" is not subclinical: improvement after adrenalectomy in 9 patients". Surgery. 142 (6): 900–5, discussion 905.e1. doi:10.1016/j.surg.2007.10.001. PMID 18063074.

Template:WH Template:WS